secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001127537-23-000032
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q2 revenue $17.2M (+23% YoY), raises FY2023 guidance to $64-66M
-----------------------------------------------------------------------

- Record worldwide revenue $17.2M, up 23% YoY; US revenue $11.0M up 28% YoY.
- Gross margin 74% (vs 75% prior year); net loss $16.2M ($0.43/share).
- Raised 2023 revenue guidance to $64-66M (from $63-65M); operating expenses maintained at $112-114M.
- Added 15 new US Zephyr Valve treatment centers in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753723000032/0001127537-23-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753723000032/lung-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001127537-23-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer